Background: The coronavirus illness of 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (COVID-2) (SARS-CoV-2). Although systemic inflammation and lung complications can result in significant morbidity and mortality, cardiovascular issues can also occur. Aim of The Work: Reducing risk of myocardial infarction in patients with COVID-19. Subjects and methods: This Case-control study was conducted in Shark El-Madina hospital in Alexandria on 129 covid-19 patients divided into group A: 43 suspected COVID-19 patients who developed Acute coronary syndrome (ACS), group B: 43 suspected COVID-19 patients who hasn`t developed ACS and group C: 43 patients with myocardial infarction who were not suspected for COVID-19. All patients underwent thorough general and local history taking, a physical exam, routine tests (CBC, CRP, ESR and blood gases) and CT chest as well as specialised tests like the ECG, ferritin, PT, PTT, INR, D. dimer, Troponin, and LDH. Results: There was differences between the three groups in terms of Troponin level, D-dimer, Ferritin, CRP, ALT, AST and PT Conclusion: Based on our study findings, we concluded that hypercoagulability of Acute coronary  syndrome is more likely to manifest in people with Covid 19 infection.